CardiologyASCVDEvolocumab
High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD
By MedXY|Dec 25, 2025
A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI
